Aegis Capital has issued a ‘Buy’ rating and price target of $33 on shares of Heron Therapeutics, Inc.’s (NASDAQ: HRTX) stock. The biotech company most recently announced the inclusion of SUSTOL® as part of the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Antiemesis Version 1.2017. FDA-approved SUSTOL was given the highest recommendation of evidence and consensus for use preventing acute and delayed chemotherapy-induced nausea and vomiting in patients receiving HEC or MEC regimens.
“The NCCN is an alliance of 27 leading cancer centers in the US, and this recommendation reaffirms our belief that Sustol extended-released will be the agent of choice for doctors. We believe this recommendation will drive adoption and uptake of Sustol and ultimately increase the likelihood of upside to our estimates,” Aegis analyst Jason Wittes said in a note. Heron recently reported SUSTOL net product sales of $1.3 million for the quarter and year ended December 31, 2016.
For more information visit www.herontx.com
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from cancer or pain.
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer